Developed by VHIO’s Radiomics Group in close collaboration with researchers of the Neuro-Radiology Unit at the Bellvitge University Hospital (HUB),…
Honoring the legacy of Heine Hoi Hansen and his global contribution to lung cancer research and education, the Heine H….
Today, February 29th is celebrated World Rare Disease Day with the aim of raising awareness in society about these pathologies…
The predictability of response criteria remains controversial in drug development. Numerous reviews and meta-analyses continue to question the reliability of…
In recognition of his voluntary efforts that benefit the American Society of Clinical Oncology (ASCO), major contributions to the specialty…
Recently published in Nature Protocols, VHIO’s Francisco Barriga and co-author Scott W. Lowe at the Memorial Sloan Kettering Cancer Center,…
Recently published in the journal Nature Medicine (1), results of exploratory research from the open-label phase III INTRIGUE clinical trial…
The Vall d’Hebron Institute of Oncology (VHIO) has received 52 grants this year for its research and technical staff that…
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in…
Next Sunday February 4th, coinciding with World Cancer Day, VHIO launches the Cancer 360 podcast, a series of 8 chapters…
On January 25-26, 2024, in Berlin, Germany, the JOIN4ATMP project held its Kick-off meeting, an initiative created to map, join…
“la Caixa” Foundation has subsidized a new transversal platform for next generation single-cell sequencing: UNderstanding cancer through sIngle cell seQUEncing:…